Liquisoft capsules

1. An oral pharmaceutical composition suitable for chewing, sucking, or buccal dissolution comprising a soft shell encapsulating a liquid matrix,

the shell comprising:

(a) about 20% gelatin, 150 Bloom;

(b) about 9% gelatin, 100 Bloom;

(c) about 5% hydrolyzed collagen;

(d) about 17% lycasin;

(e) about 25% glycerin;

(f) about 0.5% citric acid;

(g) about 2.5% about xylitol,

(h) about 0.2% sucralose; and

(i) about 21% water; and

the matrix comprising:

(j) about 21% polyethylene glycol 500,

(k) about 8% propylene glycol;

(l) about 1% polyvinylpyrrolidone K30;

(m) about 58% lycasin;

(n) about 1% citric acid;

(o) about 1% lactic acid;

(p) about 0.6% sucralose,

(q) about 0.6% acesulfame potassium;

(r) about 5% water;

(s) about 1% dextromethorphan hydrobromide; and

(t) about 0.1% menthol.

2. An oral pharmaceutical composition suitable for chewing, sucking, or buccal dissolution comprising a soft shell encapsulating a liquid matrix,

the shell comprising:

(a) about 27% gelatin, 100 Bloom;

(b) about 5% hydrolyzed collagen;

(c) about 17% lycasin;

(e) about 21% glycerin;

(f) about 1% propylene glycol;

(g) about 0.5% citric acid;

(h) about 2.5% xylitol;

(i) about 0.8% sucralose;

(j) about 0.1% peppermint oil;

(k) about 24% water; and

the matrix comprising:

(l) about 42% glycerin;

(m) about 2% propylene glycol;

(n) about 3% polyvinylpyrrolidone K30;

(o) about 40% sorbitol;

(p) about 0.3% citric acid;

(q) about 0.5% sucralose;

(r) about 0.1% eucalyptol;

(s) about 0.3% peppermint oil;

(t) about 10% water;

(u) about 0.004% thymol; and

(v) about 0.2% menthol.

3. An oral pharmaceutical composition suitable for chewing, sucking, or buccal dissolution comprising a soft shell encapsulating a liquid matrix:

the shell comprising:

(a) about 22% gelatin, 150 Bloom;

(b) about 10% gelatin, 100 Bloom;

(c) about 5% gelatin hydrolysate;

(d) about 20% glycerin;

(e) about 17% maltitol;

(f) about 0.5% citric acid;

(g) about 2.6% xylitol;

(h) about 0.2% sucralose;

(i) about 0.3% peppermint oil; and

(j) about 21% water; and

the matrix comprising:

(k) about 1% polyethylene glycol 400;

(l) about 19% glycerin;

(m) about 3% xylitol;

(n) about 37% maltitol;

(o) about 5% glycine;

(p) about 0.2% sucralose;

(q) about 0.04% menthol;

(r) about 0.04% peppermint oil;

(s) about 17% water; and

(t) about 2% nicotine polacrilex.

4. An oral pharmaceutical composition suitable for chewing, sucking, or buccal dissolution comprising a soft shell encapsulating a liquid matrix:

the shell comprising:

(a) about 19% gelatin, 150 Bloom;

(b) about 13% gelatin, 100 Bloom;

(c) about 2% gelatin hydrolysate;

(d) about 22% glycerin;

(e) about 14% maltitol;

(f) about 0.5% citric acid;

(g) about 2.5% xylitol;

(h) about 0.2% sucralose; and

(i) about 29% water; and

the matrix comprising:

(j) about 1% polyethylene glycol 400;

(k) about 2% glycerin;

(l) about 6% propylene glycol;

(m) about 27% sorbitol;

(n) about 3% xylitol;

(o) about 0.2% sucralose;

(p) about 0.04% menthol;

(q) about 0.04% peppermint oil;

(r) about 11% water; and

(s) about 47% bismuth subsalicylate.

5. A kit for dispensing the oral pharmaceutical composition of claim 1 , the kit comprising:

(a) at least one oral pharmaceutical composition;

(b) at least one moisture proof dispensing receptacle comprising blister or strip packs, an aluminum blister, a transparent or opaque polymer blister with pouch, polypropylene tubes, colored blister materials, tubes, bottles, and bottles optionally containing a child-resistant feature, optionally comprising a desiccant, such as a molecular sieve or silica gel; and optionally

(c) at least one daily regimen for the oral pharmaceutical composition; and

(d) an insert comprising instructions or prescribing information for the oral pharmaceutical composition.

6. A pharmaceutical combination comprising the oral pharmaceutical composition of claim 1 and one or more additional therapeutic compounds selected from NSAIDS, diphenhydramine, or codeine.

7. A method for treating, retarding the progression of, prophylaxis of, delaying the onset of, ameliorating, reducing the symptoms of inflammation, cough, cold, chest congestion, nasal congestion, sinusitis, throat or bronchial irritation, flu, fever, or pain comprising administering to a subject in need thereof the oral pharmaceutical composition of claim 1 .

8. A kit for dispensing the oral pharmaceutical composition of claim 2 , the kit comprising:

(a) at least one oral pharmaceutical composition;

(b) at least one moisture proof dispensing receptacle comprising blister or strip packs, an aluminum blister, a transparent or opaque polymer blister with pouch, polypropylene tubes, colored blister materials, tubes, bottles, and bottles optionally containing a child-resistant feature, optionally comprising a desiccant, such as a molecular sieve or silica gel; and optionally

(c) at least one daily regimen for the oral pharmaceutical composition; and

(d) an insert comprising instructions or prescribing information for the oral pharmaceutical composition.

9. A pharmaceutical combination comprising the oral pharmaceutical composition of claim 2 and one or more additional therapeutic compounds selected from chlorhexidine or ethanol.

10. A method for treating, retarding the progression of, prophylaxis of, delaying the onset of, ameliorating, reducing the symptoms of, or promoting health, including but not limited to of one or more of dry mouth, halitosis, stained teeth, oral pain, loss of enamel, refreshing breath, inhibiting onset of breath malodor, or freshening the oral cavity comprising administering to a subject in need thereof the oral pharmaceutical composition of claim 2 .

11. A kit for dispensing the oral pharmaceutical composition of claim 3 , the kit comprising:

(a) at least one oral pharmaceutical composition;

(b) at least one moisture proof dispensing receptacle comprising blister or strip packs, an aluminum blister, a transparent or opaque polymer blister with pouch, polypropylene tubes, colored blister materials, tubes, bottles, and bottles optionally containing a child-resistant feature, optionally comprising a desiccant, such as a molecular sieve or silica gel; and optionally

(c) at least one daily regimen for the oral pharmaceutical composition; and

(d) an insert comprising instructions or prescribing information for the oral pharmaceutical composition.

12. A pharmaceutical combination comprising the oral pharmaceutical composition of claim 3 and one or more additional therapeutic compounds selected from bupropion or varenicline.

13. A method for treating, retarding the progression of, prophylaxis of, delaying the onset of, ameliorating, or reducing the symptoms of, or promoting health, including but not limited to cessation of urge to smoke, satiating nicotine desire, nicotine-replacement therapy, or smoking cessation therapy comprising administering to a subject in need thereof the oral pharmaceutical composition of claim 3 .

14. A kit for dispensing the oral pharmaceutical composition of claim 4 , the kit comprising:

(a) at least one oral pharmaceutical composition;

(b) at least one moisture proof dispensing receptacle comprising blister or strip packs, an aluminum blister, a transparent or opaque polymer blister with pouch, polypropylene tubes, colored blister materials, tubes, bottles, and bottles optionally containing a child-resistant feature, optionally comprising a desiccant, such as a molecular sieve or silica gel; and optionally

(c) at least one daily regimen for the oral pharmaceutical composition; and

(d) an insert comprising instructions or prescribing information for the oral pharmaceutical composition.

15. A pharmaceutical combination comprising the oral pharmaceutical composition of claim 4 and one or more additional therapeutic compounds selected from cimetidine, ranitidine, famotidine, ondansetron, omeprazole, lansoprazole, rabeprazole, esomeprazole, pantoprazole, calcium supplements, calcium hydroxide, alluminum hydroxide, magnesium hydroxide, or combinations thereof.

16. A method for treating, retarding the progression of, prophylaxis of, delaying the onset of, ameliorating, or reducing the symptoms of, or promoting health, including but not limited to of one or more of inflammation of the gastrointestinal tract, neoplasia, hyperthyroidism, hypercalcemia, hyperparathyroidism, parathyroid carcinoma, indigestion, heartburn, nausea, flatulence, bloating, acid reflux, irritable bowels, constipation, diarrhea, comprising administering to a subject in need thereof comprising administering to a subject in need thereof the oral pharmaceutical composition of claim 4 .